scPharmaceuticals Inc.

NasdaqGS:SCPH Stock Report

Market Cap: US$166.1m

scPharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

scPharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-32.7%

Buyback Yield

Total Shareholder Yield-32.7%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Nov 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Nov 18
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SCPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCPH's dividend payments have been increasing.


Dividend Yield vs Market

scPharmaceuticals Dividend Yield vs Market
How does SCPH dividend yield compare to the market?
SegmentDividend Yield
Company (SCPH)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.4%
Industry Average (Pharmaceuticals)2.5%
Analyst forecast (SCPH) (up to 3 years)n/a

Notable Dividend: Unable to evaluate SCPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SCPH's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SCPH has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 05:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

scPharmaceuticals Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC